Dendreon Corporation Company Profile
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
News Articles
Dendreon Gets FDA Green Light for NJ Factory
Seattle-based Dendreon (NASDAQ: DNDN) said today it has won FDA clearance to quadruple the output from the New Jersey factory where it makes its lone product, sipuleucel-T (Provenge). The drug, for me...
Aetna expands coverage of Dendreon drug, stock jumps
(Reuters) - Health insurer Aetna Inc said on Friday it will pay for a greater number of patients to receive Provenge, a prostate cancer drug made by Dendreon Corp, sending Dendreon's shares up as much...
Aetna expands coverage of Dendreon drug; stock jumps
(Reuters) - Health insurer Aetna Inc said on Friday it will pay for a greater number of patients to receive Provenge, the prostate cancer drug made by Dendreon Corp, sending Dendreon's shares up as mu...
By John Eastman:Dendreon, Dendreon. Oh the storied Dendreon (DNDN) as they say. Dendreon is a biotechnology firm that develops, commercializes, and manufacturers therapies designated for cancer treatm...
The Key Question For Dendreon: Is There Demand For Provenge?
Wall Street analysts are applauding Dendreon chief execution John Johnson for taking the tough step of cutting 600 jobs and closing one of the company’s manufacturing plants, a change that will...
Dendreon jumps on stronger 3Q Provenge sales
Dendreon Corp. said Friday that revenue from its prostate cancer therapy Provenge grew 27 percent in the third quarter, and the company's stock jumped in midday trading.Provenge was approved to great...
Dendreon Gets $28M Revenue in Q1
Seattle-based Dendreon (NASDAQ: DNDN), the maker of an immune-boosting therapy for prostate cancer, said today it generated $28.1 million in revenue in the quarter that ended March 30. Dendreon also s...
Dendreon Gets FDA Nod for New LA Cancer Drug Factory
Seattle-based Dendreon (NASDAQ: DNDN) said today that it has won clearance from the FDA to start manufacturing its immune-boosting drug for prostate cancer at a new factory in the Los Angeles area. Th...
Drugs and Medications
None
PubMed Articles
New treatments for metastic prostate cancer.
The FDA has approved 2 new treatments for castration-resistant (formerly called hormone-refractory) prostate cancer. Sipuleucel-T (Provenge - Dendreon) s the first immunotherapy approved for treatment...
Sipuleucel-T, the first autologous cellular immunotherapy approved by the United States Food and Drug Administration, is designed to stimulate an immune response to prostate cancer. Sipuleucel-T is ma...
Clinical Trials
None
Companies
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of no...
Dendreon Corporation (Nasdaq: DNDN) is a Seattle-based biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel the...
Biotech Synergy has secured in San Diego the necessary competences to bring this promising multi epitope cancer vaccine to latest stage development. Contrary to Dendreon individua...
HealthCare Ventures is a leading venture capital firm specializing in life science industry investing. At HealthCare Ventures we concentrate our investment dollars on life science companies showing hi...
More Information about "Dendreon Corporation" on BioPortfolio
We have published hundreds of Dendreon Corporation news stories on BioPortfolio along with dozens of Dendreon Corporation Clinical Trials and PubMed Articles about Dendreon Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Dendreon Corporation Companies in our database. You can also find out about relevant Dendreon Corporation Drugs and Medications on this site too.
